BioAge Labs, Inc.

BioAge Labs, Inc. is a biotechnology firm based in the US that specializes in developing therapies aimed at metabolic aging and related diseases, utilizing multi-omics data for targeted solutions. Founded in 2015 and headquartered in Richmond, US, BioAge Labs, Inc. focuses on innovative approaches to tackle metabolic aging.

The company has engaged in 5 deals, with the most recent being a SERIES D funding round that raised USD 194. 391 mn on September 25, 2024, led by Sofinnova Investments. The company was co-founded by Eric Morgen and Kristen Fortney, who also serves as the CEO. BioAge Labs has not undergone any notable business pivots or changes in strategy since its inception.

BioAge Labs specializes in developing innovative therapies targeting metabolic aging and related diseases. Their primary offerings include BGE-102, an anti-inflammatory agent aimed at counteracting chronic inflammation tied to cardiovascular risks and metabolic disorders, and therapies focused on the apelin receptor APJ, which are designed to enhance weight loss and restore body composition in preclinical obesity models. The company employs a human-first discovery platform that utilizes proprietary multi-omics data to identify molecular mediators of aging, enabling the development of targeted pipeline programs addressing key pathways in metabolic aging. BioAge Labs primarily serves healthcare providers and pharmaceutical companies engaged in metabolic disease treatment and prevention, with a market focus that extends across North America and Europe.

BioAge Labs generated revenue of USD 8. 995 mn in 2025, with a reported EBITDA of USD -92. 567 mn for the same year. The company’s revenue generation framework is structured around partnerships and clinical trial collaborations with pharmaceutical companies and healthcare institutions.

It engages in B2B transactions, supplying its innovative solutions for use in clinical settings and research applications. While specific pricing information for its flagship products, such as BGE-102 and APJ-targeting therapies, is not disclosed, revenue is derived from licensing agreements, partnerships for drug development, and participation in clinical research funding. The anticipated IND submissions and clinical trial advancements suggest potential income streams from collaborations and licensing fees, reflecting the company’s broader strategy to monetize its research and development efforts as they progress through various clinical phases. In September 2024, BioAge Labs, Inc.

raised USD 198 mn in an IPO, selling 11 million shares at USD 18 per share on the Nasdaq Global Select Market under the ticker symbol "BIOA. " The company plans to utilize this funding to support the launch of new products targeting metabolic aging and to expand its market presence in North America and Europe by the end of 2025. The IPO also includes an option for underwriters to purchase an additional 1. 65 million shares, enhancing future financial flexibility.

Following the transaction, Andreessen Horowitz and Khosla Ventures retained minority stakes of 6. 19% and 5. 26%, respectively, indicating strong investor confidence.